What is Diasmoke

A Randomized Controlled Multicentre Study evaluating changes in Cardiovascular Risk Factors in Smokers with type 2 Diabetes Mellitus after switching from Tobacco Cigarettes to Combustion-Free Nicotine Delivery Systems: DIASMOKE 2.0 Study

You Know Diabetes

Living with diabetes means facing the choice of a healthy lifestyle every day.

Having diabetes means having a disease that often raises blood sugar levels in a worrying way.

Most of the food a person eats is turned into glucose (a kind of sugar) which the body’s cells can use for energy.

There are several types of diabetes.

Type 2 is the most common in adults and accounts for over 90% of all diabetes cases.

Fewer people have type 1 diabetes, which more often develops in children, adolescents, or young adults.

Smoking and diabetes are a bad combination. Regardless of the type of diabetes you have, smoking makes your diabetes harder to control.

If you have diabetes and smoke, you are more likely to have serious diabetes-related health problems. Smokers with diabetes have a higher risk of serious complications.

What is Diasmoke

Little is known about the impact of combustion-free nicotine delivery sistem on T2DM patients who smoke. DIASMOKE (Assessing the impact of combustion free-nicotine delivery technologies in Diabetic Smokers) is an international, multicenter, open label randomized controlled study designed to determine wheter T2DM cigarette smokers switching to CF-NDS experience measurable improvement in cardiovascular risk parameters as a consequence of avoiding exposure to cigarette smoke toxicants.

This study aims to test the hypothesis that avoiding exposure to cigarette smoke toxicants may translate to measurable improvement in cardiovascular risk factors and functional parameters when type 2 diabetes mellitus (T2DM) patients who smoke switch to using C-F NDS compared with T2DM patients who continue to smoke conventional tobacco products.

Your health will be monitored and monitored continuously.

What Does the Study Involve?

The study involves recruiting a total 576 patients will be randomized to either a control arm, in which they will be offered referral to smoking cessation programs or to an intervention arm, in which they will be assigned to C-F NDS use.

What is the Aim of Diasmoke?

Aim of Diasmoke is to determine whether type 2 diabetes mellitus cigarettes smokers whose switch to combustion free nicotine delivery system experience measurable improvements in cardiovascular risk parameters

Why participate in Diasmoke

Monitoring and medical supervision than would usually be available through standard NHS care and important research support for diabetes prevention and treatment. Each participant will be offered access to local free smoking cessation programs.

What is the purpose of the study?

This study investigates whether vaping or using E-cigarettes reduces the risk of cardiovascular (heart and circulation) disease as compared to normal smoking. The results of the study may help us to understand more about the risks of vaping or e-cigarettes and normal cigarettes for diabetes patients who are smokers.

What do we ask you?

Before randomization, all smokers will be reminded of the risks associated with smoking and will be offered a free smoking cessation program according to standard local guidelines and depending on the local availability of antismoking services. Everyone who joins the study will be randomly chosen to be in one of two groups of participants. One group will be asked to carry on smoking their usual cigarettes for the duration of the study, and the second group will be asked to switch to vaping.

Duration

The study will last approximately 2 years in total. After the basic checkup, you will be asked to come back for another four checkups after 3 months, 6 months, one year and two years.